Skip to main content
OSTI.GOVU.S. Department of Energy Office of Scientific and Technical Information
U.S. Department of Energy
Office of Scientific and Technical Information
 

Nucleic acids encoding HIV-1 GP140 immunogens comprising modified NHR1 regions that stabilize pre-fusion conformations

Patent ·
OSTI ID:1892576
; ; ; ; ; ;
The present invention provides HIV-1 vaccine immunogens. Some of the immunogens contain a soluble gp140-derived protein that harbors a modified N-terminus of the HR1 region in gp41. Some of the immunogens contain an HIV-1 Env-derived trimer protein that is presented on a nanoparticle platform. The invention also provides methods of using the HIV-1 vaccine immunogens for eliciting an immune response or treating HIV infections.
Research Organization:
Argonne National Laboratory (ANL), Argonne, IL (United States)
Sponsoring Organization:
USDOE; National Institutes of Health (NIH)
DOE Contract Number:
AC02-06CH11357
Assignee:
The Scripps Research Institute (Village of La Jolla, CA)
Patent Number(s):
11,236,134
Application Number:
16/780,495
OSTI ID:
1892576
Country of Publication:
United States
Language:
English

References (19)

Alanine Scanning Mutagenesis of HIV-1 gp41 Heptad Repeat 1: Insight into the gp120−gp41 Interaction journal May 2010
Cleavage-Independent HIV-1 Env Trimers Engineered as Soluble Native Spike Mimetics for Vaccine Design journal April 2015
Stabilizing the Native Trimer of HIV-1 Env by Destabilizing the Heterodimeric Interface of the gp41 Postfusion Six-Helix Bundle journal June 2014
Highly Stable Trimers Formed by Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Fused with the Trimeric Motif of T4 Bacteriophage Fibritin journal May 2002
Structural Mechanism of Trimeric HIV-1 Envelope Glycoprotein Activation journal July 2012
Presenting native-like HIV-1 envelope trimers on ferritin nanoparticles improves their immunogenicity journal September 2015
Rational HIV Immunogen Design to Target Specific Germline B Cell Receptors journal March 2013
Effectiveness of a novel immunogenic nanoparticle platform for Toxoplasma peptide vaccine in HLA transgenic mice journal May 2014
Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 journal September 2002
Single-Chain Soluble BG505.SOSIP gp140 Trimers as Structural and Antigenic Mimics of Mature Closed HIV-1 Env journal March 2015
Murine Antibody Responses to Cleaved Soluble HIV-1 Envelope Trimers Are Highly Restricted in Specificity journal August 2015
Mutations That Destabilize the gp41 Core Are Determinants for Stabilizing the Simian Immunodeficiency Virus-CPmac Envelope Glycoprotein Complex journal April 2002
Cleavage strongly influences whether soluble HIV-1 envelope glycoprotein trimers adopt a native-like conformation journal October 2013
Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution journal May 2000
Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits journal January 2000
Structure-Guided Redesign Increases the Propensity of HIV Env To Generate Highly Stable Soluble Trimers journal December 2015
The Structure of Docking Domains in Modular Polyketide Synthases journal August 2003
Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins journal June 2000
A Next-Generation Cleaved, Soluble HIV-1 Env Trimer, BG505 SOSIP.664 gp140, Expresses Multiple Epitopes for Broadly Neutralizing but Not Non-Neutralizing Antibodies journal September 2013

Similar Records

Related Subjects